Portal de investigación
Phase II Study Of Tarlatamab Alone Or in Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
GRUPO ESPAÑOL DE TUMORESNEUROENDOCRINOS Y ENDOCRINOS (GETNE)
Cita
Phase II Study Of Tarlatamab Alone Or in Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin. (GETNE T2419). GRUPO ESPAÑOL DE TUMORESNEUROENDOCRINOS Y ENDOCRINOS (GETNE). 2026IP:ÁNGEL AGUSTÍN SEGURA HUERTA.